StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ultragenyx Pharmaceutical operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ultragenyx Pharmaceutical's operating cash flow for the twelve months ending Jun 30, 2026 was -$485.00M. For fiscal 2025 it was -$466.00M. The highest annual figure on record is -$12.50M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$466.00M–
FY2024Dec 31, 2024-$414.00M–
FY2023Dec 31, 2023-$475.00M–
FY2022Dec 31, 2022-$380.47M–
FY2021Dec 31, 2021-$338.70M–
FY2020Dec 31, 2020-$132.22M–
FY2019Dec 31, 2019-$345.38M–
FY2018Dec 31, 2018-$290.57M–
FY2017Dec 31, 2017-$253.84M–
FY2016Dec 31, 2016-$160.98M–
FY2015Dec 31, 2015-$105.98M–
FY2014Dec 31, 2014-$44.63M–
FY2013Dec 31, 2013-$31.20M–
FY2012Dec 31, 2012-$12.50M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$97.00M–
Q1 FY2026Mar 31, 2026-$197.00M–
Q4 FY2025Dec 31, 2025-$99.83M–
Q3 FY2025Sep 30, 2025-$91.17M–
Q2 FY2025Jun 30, 2025-$109.00M–
Q1 FY2025Mar 31, 2025-$166.00M–
Q4 FY2024Dec 31, 2024-$79.32M–
Q3 FY2024Sep 30, 2024-$67.00M–
Q2 FY2024Jun 30, 2024-$76.96M–
Q1 FY2024Mar 31, 2024-$190.73M–
Q4 FY2023Dec 31, 2023-$84.10M–
Q3 FY2023Sep 30, 2023-$117.87M–
Q2 FY2023Jun 30, 2023-$116.16M–
Q1 FY2023Mar 31, 2023-$156.87M–
Q4 FY2022Dec 31, 2022-$90.34M–
Q3 FY2022Sep 30, 2022-$95.35M–
Q2 FY2022Jun 30, 2022-$77.26M–
Q1 FY2022Mar 31, 2022-$117.52M–
Q4 FY2021Dec 31, 2021-$54.34M–
Q3 FY2021Sep 30, 2021-$59.65M–
Q2 FY2021Jun 30, 2021-$65.36M-174.8%
Q1 FY2021Mar 31, 2021-$159.35M–
Q4 FY2020Dec 31, 2020-$62.45M–
Q3 FY2020Sep 30, 2020-$61.97M–
Q2 FY2020Jun 30, 2020$87.35M–
Q1 FY2020Mar 31, 2020-$95.15M–
Q4 FY2019Dec 31, 2019-$72.04M–
Q3 FY2019Sep 30, 2019-$88.51M–
Q2 FY2019Jun 30, 2019-$89.06M–
Q1 FY2019Mar 31, 2019-$95.78M–
Q4 FY2018Dec 31, 2018-$55.85M–
Q3 FY2018Sep 30, 2018-$69.16M–
Q2 FY2018Jun 30, 2018-$76.08M–
Q1 FY2018Mar 31, 2018-$89.48M–
Q4 FY2017Dec 31, 2017-$81.82M–
Q3 FY2017Sep 30, 2017-$61.99M–
Q2 FY2017Jun 30, 2017-$48.82M–
Q1 FY2017Mar 31, 2017-$61.21M–
Q4 FY2016Dec 31, 2016-$47.68M–
Q3 FY2016Sep 30, 2016-$28.75M–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?